Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC Implications for disease assessment and management》.pdf

Lung Cancer 88 (2015) 355–359 Contents lists available at ScienceDirect Lung Cancer j o u r n a l h o m e p ag e: w w w. elsev /locate/lung can Case Report Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management a a b Sai-Hong Ignatius Ou ,b,∗ , Samuel J. Klempner ,b , Michele C. Azada , Veronica Rausei-Mills c , Christopher Duma d a Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States b Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States c Department of Pathology, Hoag Memorial Hospital Presbyterian, One Hoag Drive, Newport Beach, CA 92658, United States d Hoag Neurosciences Institute, Director, Hoag Brain Tumor Program, Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92663, United States a r t i c l e i n f o a b s t r a c t Article history: Objectives: Radiation necrosis presenting as pseudoprogression (PsP) is relatively common after radia- Received 13 February 2015 tion and temozolomide (TMZ) treatment in glioblastoma multiforme (GBM), especially among patients Received in revised form 18 March 2015 with GBM that harbors intrinsic increased responsiveness to TMZ (methylated O6-methylguanine–DNA Accepted 23 March 2015